Policy | August 03, 2021
API exports surpass imports by value in 2020-21
The govt has rolled out three schemes for promoting the manufacture of API
The govt has rolled out three schemes for promoting the manufacture of API
The Phase III clinical trial for NONS is expected to be completed by Q4 2021.
The company has an outlay of Rs 120-140 crore as R & D expense for FY 22
Ayush Ministry will conduct the study along with the UK’s London School of Hygiene and Tropical Medicine
WHO prequalification enables the procurement of ROTAVAC 5D by UN agencies namely UNICEF and PAHO
The company posted net profit of Rs.89.20 crores for the period ended June 30, 2020.
The Cephalosporin Injectables plant has a total capacity of 26.4 million vials per year while Ethiopia is having a demand for 16 million vials
The company proposes to utilise the net proceeds from the fresh issue towards payment of outstanding purchase consideration
The company confirms an upward revision to its 2021 Outlook, reflecting the expectation to achieve mid-teens CER sales growth
Q1 FY22 consolidated revenue grew 6% to Rs. 1,808 crore from Rs. 1,712 crore in Q1 FY21. Q1 FY22 Net Profit was Rs. 84 crore (vs. Rs. 149 crore in Q1 FY21).
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
